SWOG clinical trial number
SWOG-9245

Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary

Closed
Phase
Abbreviated Title
ANCILLARY: Central Lymphoma Tissue Repository for Relapsed or Recurrent Disease
Activated
03/15/1993
Participants
NCORP, Members

Research committees

Lymphoma

Eligibility Criteria Expand/Collapse

For patients with prior registration to a Southwest Oncology Group-coordinated treatment protocol for previously untreated non-Hodgkin's lymphoma.

Other Clinical Trials

SWOG Clinical Trial Number
S2506

MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
69%
Open
Phase